| Gilead Sciences, Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120108601 | CRYSTALLINE PYRIDAZINE COMPOUND - A crystalline compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections | 05-03-2012 |
| 20120107274 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT - Provided are methods for treating Orthomyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: | 05-03-2012 |
| 20120093890 | INHALABLE AZTREONAM FOR TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS - A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by | 04-19-2012 |
| 20120065227 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS - The present invention discloses triazolopyridinone derivatives for use as inhibitors of stearoyl-CoA desaturase having the structure of Formula I: | 03-15-2012 |
| 20120045412 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS - The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. | 02-23-2012 |
| 20120027752 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS - Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: | 02-02-2012 |
| 20120020921 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT - Provided are prodrugs of pyrrolo[1,2-f][1,2,4]triazin-7-yl nucleoside phosphates wherein the 1′ position of the nucleoside sugar is substituted with CN. The compounds, compositions, and methods provided are useful for the treatment Hepatitis C infections. | 01-26-2012 |
| 20120009147 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT - Provided are select imidazo[1,2-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 2′ position of the nucleoside sugar is substituted with halogen and carbon substituents. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections caused by both wild type and mutant strains of HCV. | 01-12-2012 |
| 20120004267 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS - The present invention relates to compounds of Formula (I): | 01-05-2012 |
| 20120003215 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT - The invention provides compounds of Formula I or Formula II: | 01-05-2012 |
| 20110306541 | METHODS FOR TREATING HCV - This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions. | 12-15-2011 |
| 20110293563 | 1'SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT - Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. | 12-01-2011 |
| 20110288053 | ANTIVIRAL PHOSPHONATE ANALOGS - The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 11-24-2011 |
| 20110275623 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS - This invention provides compounds of the formula: | 11-10-2011 |
| 20110275622 | BI-FUNCTIONAL QUINOLINE ANALOGS - Provided are compounds of Formula I: | 11-10-2011 |
| 20110257127 | A2B ADENOSINE RECEPTOR ANTAGONISTS - Disclosed are novel compounds that are A | 10-20-2011 |
| 20110236348 | MODULATORS OF TOLL-LIKE RECEPTOR 7 - The present invention includes therapeutic methods that include the administration of a compound of Formula I or II: | 09-29-2011 |
| 20110230654 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS - Provided are processes and intermediates for the syntheses of nucleosides of pyrrolo[1,2-f][1,2,4]triazinyl and imidazo[1,24][1,2,4]triazinyl heterocycles of Formula I. | 09-22-2011 |
| 20110230431 | FOSFOMYCIN/TOBRAMYCIN COMBINATIONS FOR THE TREATMENT AND PREVENTION OF OPHTHALMIC, OTOLOGICAL AND DERMATOLOGICAL INFECTIONS - Provided are topical fosfomycin-tobramycin compositions for the treatment and/or prevention of ophthalmic, otological, and dermatologic inflammation and/or bacterial infections and methods of treating ophthalmic, otological and dermatological inflammation and/or bacterial infections. | 09-22-2011 |
| 20110223131 | ANTIVIRAL COMPOUNDS - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 09-15-2011 |
| 20110212964 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS - The present application provides for a compound of Formula I, | 09-01-2011 |
| 20110212030 | Nucleic Acid Ligand Complexes - This invention discloses a method for preparing a therapeutic or diagnostic complex comprised of a nucleic acid ligand and a lipophilic compound or non-immunogenic, high molecular weight compound by identifying a nucleic acid ligand by SELEX methodology and associating the nucleic acid ligand with a lipophilic compound or a non-immunogenic, high molecular weight compound. The invention further discloses complexes comprising one or more nucleic acid ligands in association with a lipophilic compound or non-immunogenic, high molecular weight compound. | 09-01-2011 |
| 20110196021 | High Affinity Nucleic Acid Ligands of Complement System Proteins - Methods are described for the identification and preparation of high-affinity Nucleic Acid Ligands to Complement System Proteins. Methods are described for the identification and preparation of high affinity Nucleic Acid Ligands to Complement System Proteins C1q, C3 and C5. Included in the invention are specific RNA ligands to C1q, C3 and C5 identified by the SELEX method. | 08-11-2011 |
| 20110184002 | METHOD OF TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS - The invention is related to methods of preventing and treating hepatic fibrosis using A | 07-28-2011 |
| 20110178129 | INHIBITORS OF FLAVIVIRIDAE VIRUSES - Provided are compounds of Formula I: | 07-21-2011 |
| 20110178058 | INHIBITORS OF FLAVIVIRIDAE VIRUSES - Provided are compounds of Formula I: | 07-21-2011 |
| 20110172192 | METHOD AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES - A compound of formula 1 | 07-14-2011 |
| 20110171196 | METHODS OF TREATMENT AND USES FOR CAMKII AND ITS INTERACTION WITH HDACS AND CALPAIN - The present invention provides for methods of treating and cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension comprising the use of CaMKII-HDAC binding domains. The present invention discloses not only the fact that CaMKII binds to HDAC4 at a specific site, but that HDAC4 may dimerize with other HDACs. Both events can lead to export of HDACs from the nucleus to the cytoplasm, an event associated with the development of heart disease. Thus the methods of treatment and the screening methods of the present invention are novel attempts to prevent, treat or identify therapies for cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension. | 07-14-2011 |
| 20110160458 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS - The invention provides synthetic processes and synthetic intermediates that can be used to prepare 4-oxoquinolone compounds having useful integrase inhibiting properties. | 06-30-2011 |
| 20110160162 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS - Disclosed are prodrugs of A | 06-30-2011 |
| 20110150836 | METHODS OF TREATING HBV AND HCV INFECTION - This application relates to a purine derivative and pharmaceutical compositions which are useful for treating a hepatitis B viral infection or a hepatitis C viral infection. | 06-23-2011 |
| 20110144050 | SALTS OF HIV INHIBITOR COMPOUNDS - The invention is related to salts of anti-viral compounds, compositions containing such salts, and therapeutic methods that include the administration of such salts, as well as to processes and intermediates useful for preparing such salts. | 06-16-2011 |
| 20110135604 | ANTIVIRAL COMPOUNDS - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 06-09-2011 |
| 20110135599 | ANTIVIRAL COMPOUNDS - The present application includes novel inhibitors of HCV, compositions containing such compounds, therapeutic methods that include the administration of such compounds. | 06-09-2011 |
| 20110130559 | Methods to Manufacture 1,3-Dioxolane Nucleosides - This application provides a process for preparing enantiomerically pure β-D-dioxolane nucleosides. In particular, a new synthesis of (−)-DAPD, suitable for large scale development, is described. In one embodiment the invention provides a process for preparing a substantially pure β-D- or β-L-1,3-dioxolane nucleosides comprising a) preparing or obtaining an esterified 2,2-dialkoxy ethanol; b) cyclizing the esterified 2,2-dialkoxy ethanol with glycolic acid to obtain a 1,3-dioxolane lactone; c) resolving the 1,3-dioxolane lactone to obtain a substantially pure D- or L-lactone; d) selectively reducing and activating the D- or L-chiral lactone to obtain a substantially pure D- or L-1,3-dioxolane; e) coupling the D- or L-1,3-dioxolane to an activated and/or protected purine or pyrimidine base; and f) optionally purifying the nucleoside to obtain a substantially pure protected β-D- or β-L-1,3-dioxolane nucleoside. | 06-02-2011 |
| 20110130362 | A2B ADENOSINE RECEPTOR ANTAGONISTS - Disclosed are novel compounds that are A | 06-02-2011 |
| 20110124627 | MODULATORS OF TOLL-LIKE RECEPTORS - The present application includes novel modulators of TLRs, compositions containing such compounds, therapeutic methods that include the administration of such compounds. | 05-26-2011 |
| 20110124589 | INHALED FOSFOMYCIN/TOBRAMYCIN FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE - The present invention provides the use of an aerosol formulation comprising fosfomycin and tobramycin in the treatment of patients with chronic obstructive pulmonary disease (COPD) who are experiencing or are at risk of experiencing acute exacerbations of COPD. Formulations for such use and methods of treating humans with COPD are also provided. | 05-26-2011 |
| 20110123493 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS - Pyrido(3,2-d)pyrimidine derivatives represented by the structural formula (Ia): wherein, R | 05-26-2011 |
| 20110098248 | MODULATORS OF TOLL-LIKE RECEPTORS - The present application includes novel modulators of TLRs, compositions containing such compounds, therapeutic methods that include the administration of such compounds. | 04-28-2011 |
| 20110082112 | ANTIVIRAL PHOSPHINATE COMPOUNDS - The invention is related to a method of treating disorders associated with hepatitis C by administering to an individual a pharmaceutical composition which comprises a therapeutically effective amount of an anti-viral phosphinate compound. | 04-07-2011 |
| 20110081314 | ANTIVIRAL PHOSPHINATE COMPOUNDS - The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 04-07-2011 |
| 20110076276 | Novel HIV reverse transcriptase inhibitors - The invention is related to compounds of Formula (I): | 03-31-2011 |
| 20110070194 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT - Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 2′ position of the nucleoside sugar is substituted with halogen and carbon substitutents. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections caused by both wild type and mutant strains of HCV. | 03-24-2011 |
| 20110065631 | PROCESS FOR PREPARATION OF HIV PROTEASE INHIBITORS - A process for the synthesis of bisfuran intermediates of formula (0) useful for preparing antiviral HIV protease inhibitor compounds is hereby disclosed. Furthermore disclosed is a HIV protease inhibitor of formula (IV) as well as various intermediates thereof. | 03-17-2011 |
| 20110052527 | IMIDAZOPYRIDINYL THIAZOLYL HISTONE DEACETYLASE INHIBITORS - A compound of general Formula (I) having histone deacetylase (HDAC) and/or CDK inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. | 03-03-2011 |
| 20110020278 | INHIBITORS OF FLAVIVIRIDAE VIRUSES - Provided are compounds of Formula I: | 01-27-2011 |
| 20110009411 | THERAPEUTIC COMPOSITIONS AND THE USE THEREOF - The invention includes methods, compositions, and kits useful for treating a viral infection by coadministering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with lopinavir or a pharmaceutically acceptable salt thereof. | 01-13-2011 |
| 20110009410 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS - The present invention relates to compounds of Formula (I): | 01-13-2011 |
| 20100324060 | PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HCV - This invention relates to combinations of Compound 1 and Compound 2 which are useful for treating hepatitis C virus infection. | 12-23-2010 |
| 20100324059 | PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HCV - This invention relates to combinations of Compound 1 and Compound 2 which are useful for treating hepatitis C virus infection. | 12-23-2010 |
| 20100323989 | PHARMACEUTICAL COMBINATIONS USEFUL FOR TREATING HCV - This invention relates to combinations of Compound 1 and Compound 2 which are useful for treating hepatitis C virus infection. | 12-23-2010 |
| 20100310500 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS - The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. | 12-09-2010 |
| 20100305117 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS - The invention provides 4,6-di- and 2,4,6-tri-substituted pteridine derivatives with a specific substitution pattern which exhibit a significant and selective activity against certain types of viral infections, in particular selectively inhibit replication of Flaviridae such as the hepatitis C virus, and are useful for the prevention and treatment of such viral infections. | 12-02-2010 |
| 20100292480 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS - The invention provides synthetic processes and synthetic intermediates that can be used to prepare 4-oxoquinolone compounds having useful integrase inhibiting properties. | 11-18-2010 |
| 20100285122 | TABLETS FOR COMBINATION THERAPY - The invention provides solid dose forms (e.g. tablets) comprising a compound of Formula I, a compound of Formula II, a compound of Formula III and a salt of Formula IV. | 11-11-2010 |
| 20100203015 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT - Provided are thieno[3,4-d]pyrimidin-7-yl and furo[3,4-d]pyrimidin-7-yl ribosides, riboside phosphates and prodrugs thereof as well as intermediates and methods of preparation. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections. | 08-12-2010 |
| 20100189687 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS - The present application provides for a compound of Formula IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent. | 07-29-2010 |
| 20100173939 | ANTIVIRAL COMPOUNDS - The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infection. | 07-08-2010 |
| 20100160403 | HCV NS3 PROTEASE INHIBITORS - The present invention relates to macrocyclic compounds of formula (Ia) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections. | 06-24-2010 |
| 20100160370 | METHOD OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS - The present invention relates to methods, uses, and compositions comprising the caspase inhibitor (R)-N-((2S,3S)-2-(fluoromethyl)-2-hydroxy-5-oxo-tetrahydrofuran-3-yl)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydroisoxazole-5-carboxamide, or a pharmaceutically acceptable salt thereof. | 06-24-2010 |
| 20100152444 | NOVEL PYRIDAZINE COMPOUND AND USE THEREOF - A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections | 06-17-2010 |
| 20100143301 | MODULATORS OF TOLL-LIKE RECEPTORS - Provided are modulators of TLRs of Formula II: | 06-10-2010 |
| 20100143299 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS - This invention provides the treatment of viral infections with a 4,6-disubstituted or 2,4,6-trisubstituted quinazoline derivative represented by the structural formula [(I)] wherein: R | 06-10-2010 |
| 20100119590 | Method of drug loading in liposomes by gradient - A method for encapsulation of pharmaceutical agents (e.g., antineoplastic agents) in liposomes is provided, having preferably a high drug:lipid ratio. Liposomes can be made by a process that loads the drug by an active mechanism using a transmembrane pH gradient. Using this technique, trapping efficiencies approach 100%. Drug:lipid ratios employed are higher than for older traditional liposome preparations, and the release rate of the drug from the liposomes is reduced. After loading, residual acid is quenched with a quenching agent that is base permeable at low temperatures. The residual aciditiy is thus reduced and chemical stability (e.g. against hydrolysis) is enhanced. The stability of both the liposome and the pharmaceutical agent is thus maintained, prior to administration. The pH gradient is, however, present when the liposome is administered in vivo because the quenching agent rapidly exits the liposome. | 05-13-2010 |
| 20100104532 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT - The invention provides unsaturated phosphonates of Formula I or a tautomer or pharmaceutically accepatble salt thereof, as described herein, as well as pharmaceutical compositions comprising the compounds, and therapeutic methods comprising administering the compounds. The compounds have anti-viral properties and are useful for treating viral infections (e.g. HCV) in animals (e.g. humans). | 04-29-2010 |
| 20100093667 | SALTS OF HIV INHIBITOR COMPOUNDS - The invention is related to salts of anti-viral compounds, compositions containing such salts, and therapeutic methods that include the administration of such salts, as well as to processes and intermediates useful for preparing such salts. | 04-15-2010 |
| 20100063059 | NOVEL PYRIDAZINE COMPOUND AND USE THEREOF - A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections. Methods of making and formulating compound (1) are provided. | 03-11-2010 |
| 20100034827 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS - The invention is related to compounds of Formula (I), (II), or (III); or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds. | 02-11-2010 |
| 20100029922 | Platelet Derived Growth Factor (PDGF) Nucleic Acid Ligand Complexes - This invention discloses a method for preparing a complex comprised of a PDGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a PDGF Nucleic Acid Ligand by SELEX methodology and associating the PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more PDGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a PDGF Nucleic Acid Ligand or Complex and methods for making the same. | 02-04-2010 |
| 20100022508 | ANTIVIRAL COMPOUNDS - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 01-28-2010 |
| 20100021425 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT - Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. | 01-28-2010 |
| 20100008867 | METHOD OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS - The present invention relates to methods, uses, and compositions comprising the caspase inhibitor (R)-N-((2S,3S)-2-(fluoromethyl)-2-hydroxy-5-oxo-tetrahydrofuran-3-yl)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydroisoxazole-5-carboxamide, or a pharmaceutically acceptable salt thereof. | 01-14-2010 |
| 20090324729 | USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT - The invention provides a composition comprising, a compound of formula (I): | 12-31-2009 |
| 20090324543 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS - 2-amino-pyrido(3,2-d)pyrimidine derivatives with a specific substitution pattern on positions 4 and 6 of the core structure are useful in the treatment or prevention of an infection due to a virus from the Flaviviridae family, especially HCV, when administered to a patient in a therapeutically effective amount. | 12-31-2009 |
| 20090318456 | SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS - Tri-substituted pteridines and tetra-substituted pteridines exhibit a significant and selective activity against certain types of viral infections, in particular they selectively inhibit the replication of the hepatitis C virus, and are useful for the prevention and treatment of such infections. | 12-24-2009 |
| 20090318396 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY - New chemical entities which comprise corticosteroids and phosphorylated β-agonists for use in therapy and compositions comprising and processes for preparing the same. | 12-24-2009 |
| 20090317361 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT - Provided are imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. | 12-24-2009 |
| 20090306112 | ANTIVIRAL PROTEASE INHIBITORS - The invention is related to compounds of Formula I or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds. | 12-10-2009 |
| 20090306054 | INTEGRASE INHIBITORS - Tricyclic compounds of formulae I-III, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed. | 12-10-2009 |
| 20090291952 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS - The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent. | 11-26-2009 |
| 20090291922 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF - Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV, | 11-26-2009 |
| 20090291921 | INTEGRASE INHIBITORS - Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed. | 11-26-2009 |
| 20090285782 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS - This invention provides quinazoline derivatives represented by the structural formula: (I); wherein: R | 11-19-2009 |
| 20090258840 | METHOD AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES - A compound of formula (1), and/or its salts, tautomers or solvates is used to treat hematological malignancies. In an embodiment, an organic acid salt of compound 1 is provided for general use in treatment of neoplasms, and in a further embodiment the salt is stabilized with carbohydrate. | 10-15-2009 |
| 20090257978 | Antiviral coumpounds - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 10-15-2009 |
| 20090247487 | Combination Therapy to Treat Hepatitis B Virus - The present invention is directed to a method for treating hepatitis B virus infection in humans comprising administering a synergistically effective amount of agents having known anti-hepatitis B virus activity in combination or alternation. Specifically, the invention is directed to a method for treating hepatitis B virus infection comprising administering FTC in combination or alternation with penciclovir, famciclovir or Bis-POM-PMEA. Additionally, the invention is directed to a method for treating hepatitis B virus infection comprising administering L-FMAU in combination or alternation with DAPD, penciclovir or Bis-POM-PMEA. The invention is further directed to a method for treating hepatitis B virus infection comprising administering DAPD in combination or alternation with Bis-POM-PMEA. | 10-01-2009 |
| 20090232768 | NOVEL COMPOUNDS AND METHODS FOR THERAPY - Novel compounds having structure (1) | 09-17-2009 |
| 20090208456 | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation - The present invention relates to pharmaceutical compositions for the treatment of prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyrimidine having the general formula (A), wherein the substituents are described in the specification. The invention also relates to processes for the preparation of compounds according to the invention having above mentioned general formula, their pharmaceutically acceptable formulations and their use as a medicine or to treat or prevent viral infections. | 08-20-2009 |
| 20090202484 | MODULATORS OF TOLL-LIKE RECEPTOR 7 - The present application provides for a compound of Formula (I) or (II): or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods that include the administration of such compounds with at least one additional active agent. | 08-13-2009 |
| 20090202470 | Phosphonate Analogs of Hiv Inhibitor Compounds - The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 08-13-2009 |
| 20090186869 | Antiviral compounds - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 07-23-2009 |
| 20090175820 | INHIBITORS OF CYTOCHROME P450 - The present application provides for a compound of Formula I, | 07-09-2009 |
| 20090149648 | NUCLEOTIDE ANALOGS - Nucleotide analogs characterized by the presence of an amidate linked amino acid or an ester linked group which is bonded to the phosphorus atom of phosphonate nucleotide analogs are disclosed. The analogs comprise a phosphoamidate or ester bond that is hydrolyzed in vivo to yield a corresponding phosphonate nucleotide analog. Methods and intermediates for their synthesis and use are described. | 06-11-2009 |
| 20090149400 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF - Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV, | 06-11-2009 |
| 20090143314 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY - The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations. | 06-04-2009 |
| 20090131414 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C - Specifically substituted pyrido(3,2-d)pyrimidine derivatives having the structural formula (I) are useful for the treatment of hepatitis C. | 05-21-2009 |
| 20090124594 | INHALED AZTREONAM LYSINE FOR THE TREATMENT OF DEFICITS IN HEALTH-RELATED QUALITY-OF-LIFE IN LUNG DISEASES - Provided is a method of treating the health-related quality-of-life (HRQOL) symptoms of a lung disease, comprising the administration of an inhalable aerosole of aztreonam lysine. The method is suitable for the short term and sustainable long term treatment of HRQOL symptoms. | 05-14-2009 |
| 20090118481 | High Affinity Nucleic Acid Ligands To Lectins - This invention discloses high-affinity oligonucleotide ligands to lectins, specifically nucleic acid ligands having the ability to bind to the lectins, wheat germ agglutinin, L-selectin, E-selectin and P-selectin. Also disclosed are the methods for obtaining such ligands. This invention discloses high-affinity oligonucleotide ligands to lectins, specifically nucleic acid ligands having the ability to bind to the lectins, wheat germ agglutinin, L-selectin, E-selectin and P-selectin. Also disclosed are the methods for obtaining such ligands. | 05-07-2009 |
| 20090099366 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS - The invention provides synthetic processes and synthetic intermediates that can be used to prepare 4-oxoquinolone compounds having useful integrase inhibiting properties. | 04-16-2009 |
| 20090093482 | THERAPEUTIC COMPOSITIONS AND METHODS - The invention includes methods, compositions, and kits useful for treating a viral infection by coadministering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with lopinavir or a pharmaceutically acceptable salt thereof. | 04-09-2009 |
| 20090093467 | THERAPEUTIC COMPOSITIONS AND METHODS - The invention includes methods, compositions, and kits useful for treating a viral infection by administering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with atazanavir or a pharmaceutically acceptable salt thereof, and optionally with a compound that inhibits cytochrome P-450, or a pharmaceutically acceptable salt thereof. | 04-09-2009 |
| 20090075922 | Nucleic Acid Ligands Which Bind to Hepatocyte Growth Factor/Scatter Factor (HGF/SF) or its Receptor c-met - The invention provides nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF) and its receptor c-met. The nucleic acid ligands of the instant invention are isolated using the SELEX method. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which elevated HGF and c-met activity are causative factors. | 03-19-2009 |
| 20090060998 | LIPID-BASED DISPERSIONS USEFUL FOR DRUG DELIVERY - The invention provides lipid-based dispersion comprising, a) phosphatidyl choline; b) an anionic phospholipid; optionally c) up to 1% cholesterol by weight of total lipids; and optionally d) a therapeutic agent; wherein the mean particle size measured by dynamic light scattering is less than 100 nm. The invention also provides pharmaceutical compositions comprising such a dispersion as well as methods of producing a therapeutic effect in a mammal comprising administering an effective amount of such a dispersion. | 03-05-2009 |
| 20090048189 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS - Disclosed are tricyclic nucleoside compounds of formula (I), and methods thereof for treating viral infections mediated at least in part by a Flaviviridae family virus. | 02-19-2009 |
| 20090047252 | Antiviral compounds - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 02-19-2009 |
| 20090036460 | Crystalline pyridazine compound - A crystalline compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections | 02-05-2009 |
| 20090036408 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY - The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations. | 02-05-2009 |
| 20080312241 | Cicletanine and PKC inhibitors in the treatment of pulmonary and cardiac disorders - Embodiments of the present invention are related to novel therapeutic drugs, drug combinations, and associated methods for treating or preventing pulmonary disease, including pulmonary hypertension, pulmonary fibrosis, asthma and COPD, and heart failure, together with other pulmonary and cardiovascular diseases and their complications. More particularly, aspects of the present invention are related to the use of cicletanine and ruboxistaurin as monotherapies or in combination with other agents for treatment of disease. Cicletanine may be used as pure (+) or (−) enantiomers or as a racemic or non-racemic mixture of those enantiomers. | 12-18-2008 |
| 20080213345 | Delivering Iron to an Animal - The invention provides a method for delivery iron to an animal. This invention further provides a method for treating iron deficiency in an animal. | 09-04-2008 |
| 20080207883 | Platelet Derived Growth Factor (PDGF) Nucleic Acid Ligand Complexes - This invention discloses a method for preparing a complex comprised of a PDGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a PDGF Nucleic Acid Ligand by SELEX methodology and associating the PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more PDGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a PDGF Nucleic Acid Ligand or Complex and methods for making the same. | 08-28-2008 |
